ClinicalTrials.gg
RecruitingNCT07223307Updated Oct 27, 2026

REGULUS: MRI-guided Adaptive SABR for Liver Cancers

A Phase 2 interventional study of MRI-guided adaptive stereotactic ablative body radiotherapy (SABR) in Liver Cancer, Intrahepatic Cholangiocarcinoma and Liver Metastases, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Stanford University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Liver Neoplasms by Stanford University — 1 open to participants now, 1 under way, none of them phase 3. Liver Neoplasms · Stanford University.

Started
2026
the only one that year
Phase 2
2 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Liver Neoplasms by Stanford University, this one is the only one that started in 2026, is one of 2 in phase 2, and was the 12th registered.

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

1 of the 12 studies in Liver Neoplasms by Stanford University is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Liver Neoplasms by Stanford University, or all of them as a file.
02

Study summary

Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers

03

Conditions studied

  • Liver Cancer
  • Intrahepatic Cholangiocarcinoma
  • Liver Metastases
  • HCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed HCC, intrahepatic cholangiocarcinoma, or cancer. In the case of suspected HCC in patients with known cirrhosis, noninvasive criteria recommended by the European Association for the Study of Liver Diseases (lesion > 1 cm with arterial phase hyperenhancement and venous phase washout) or LI-RADS score of 5 may be used
  • ≥ 18 years old at time of study enrollment
  • A status
  • (ECOG) Performance Status of 0, 1, or 2
  • > 6 months
  • For women of or who are not (see Appendix F for Definition of Menopausal Status), a negative urine or serum pregnancy test must be done.
  • Ability to understand and the willingness to provide written .
  • Patients treated with prior liver-directed therapies with the exception of radioembolization are eligible for this study if they otherwise meet eligibility criteria

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with radioembolization
  • Cytotoxic chemotherapy or agent within 1 week of SABR
  • Prior radiotherapy overlapping with study treatment site
  • Female patients who are pregnant
  • to having an MRI scan or inability to tolerate MRI
  • Presence of a pacemaker or other implanted cardiac device
  • Direct tumor extension into the stomach, duodenum, small bowel or large bowel
  • Patient unable to breath hold > 15 seconds
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    MRI-guided Adaptive Stereotactic Ablative Body Radiotherapy (SABR)

    Participants will receive a single fraction of MRI-guided adaptive stereotactic ablative body radiotherapy (SABR) using the MRIdian system. Treatment includes daily adaptive planning based on MRI to optimize dose delivery to the tumor and minimize dose to surrounding normal tissue. Eovist contrast is administered before treatment to enhance visualization. Patients perform an inspiratory breath hold during radiation delivery to minimize motion.

    Radiation: MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)

Interventions

  • RadiationMRI-guided adaptive stereotactic ablative body radiotherapy (SABR)

    A single fraction of MRI-guided adaptive stereotactic ablative body radiotherapy (SABR) will be delivered using the MRIdian system. Treatment includes adaptive planning based on daily MRI imaging to update tumor and organ-at-risk contours and optimize the radiation dose. On the day of treatment, Eovist contrast is administered 20 minutes before therapy to enhance tumor visualization. Patients perform an inspiratory breath hold during radiation delivery to minimize motion. The total dose is 30-40 Gy delivered in one fraction using external beam techniques.

06

What researchers measure

Primary outcomes

  1. 1-year Overall Survival (OS)

    Overall survival will be defined as the time from treatment to death from any cause. Patients alive at the time of analysis will be censored at last follow-up.

    Time frame: 1 year after SABR

Secondary outcomes

  1. Rate of Grade ≥ 2 Gastrointestinal (GI) Adverse Events

    Proportion of participants experiencing CTCAE v5.0 grade ≥ 2 gastrointestinal adverse events (including fatigue, nausea, diarrhea, or GI pain) attributable to SABR.

    Time frame: Within 90 days of completing SABR

  2. Rate of Grade ≥ 2 Radiation Pneumonitis

    Proportion of participants experiencing CTCAE v5.0 grade ≥ 2 radiation pneumonitis attributable to SABR.

    Time frame: Within 90 days of completing SABR

  3. Rate of Grade ≥ 2 Chest Wall Toxicity

    Proportion of participants experiencing CTCAE v5.0 grade ≥ 2 chest wall toxicity attributable to SABR.

    Time frame: Within 90 days of completing SABR

  4. Change from Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life Score up to 1 Year Post-SABR

    Patient-reported global health status and quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Scores range from 0 to 100, with higher scores indicating better global health status and overall quality of life.

    Time frame: Up to 1 year post-SABR

  5. Change from Baseline in FACT-Hep Total Score up to 1 Year Post-SABR

    Patient-reported quality of life will be evaluated using the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. The FACT-Hep consists of the FACT-General (FACT-G) plus additional hepatobiliary-specific items. Total scores range from 0 to 180, with higher scores indicating better health-related quality of life.

    Time frame: Up to 1 year post-SABR

  6. Change from Baseline in COST-FACIT Total Score up to 1 Year Post-SABR

    Financial toxicity will be assessed using the Comprehensive Score for Financial Toxicity (COST-FACIT) questionnaire. Scores range from 0 to 44, with higher scores indicating lower financial toxicity (better financial well-being).

    Time frame: Up to 1 year post-SABR

  7. Rate of Patients With Total Delivery Time > 120 Minutes

    Percentage of patients with total SABR delivery time exceeding 120 minutes.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2030, 48 months after the start.

Of 73 non-industry phase 2 interventional studies under Liver Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 103. This study's planned 48 months is below that.

Counting every sponsor, half of 87 studies reached it within 57 months; a quarter within 37 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2025
First posted
Oct 31, 2025
StartActual
Jan 23, 2026
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2030
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07223307
Collaborators
Viewray Inc.
Responsible party
Sponsor
First posted
Oct 31, 2025
Start date
Jan 23, 2026
Primary completion
Jan 2030 (estimated)
Completion
Jan 2030 (estimated)
Last update
Oct 27, 2026

Study contacts

Eleanor Brown
Contact
eleanor9@stanford.edu
650-497-8966

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion